A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Latest Information Update: 10 Jan 2025
Price :
$35 *
At a glance
- Drugs Anastrozole (Primary) ; Saracatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 19 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 19 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.